Deletion of 11q in neuroblastomas drives sensitivity to PARP inhibition.
Clin Cancer Res. 2017 Aug 22;:
Authors: Sanmartín E, Muñoz L, Piqueras M, Sirerol JA, Berlanga P, Cañete A, Castel V, Font de Mora J
Abstract PURPOSE: Despite advances in multimodal therapy, neuroblastomas with hemizygous deletion in chromosome 11q (20-30%) undergo consecutive recurrences with poor outcome.